CompletedNot Applicable

A Translational Approach to Gitelman Syndrome

United States8 participantsStarted 2009-01

Plain-language summary

This study will test the response to a single dose of thiazide diuretic as a diagnostic test for Gitelman syndrome. Individuals with hypokalemic alkalosis will be enrolled. After a baseline study, they will have the response to 50 mg hydrochlorothiazide on fractional chloride excretion examined.

Who can participate

Age range21 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Institutional Review Board (IRB) approved written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization as per national regulations, must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
✓. Subject is between the ages of 21 and 60.
✓. Female subjects of child bearing potential must have a negative urine pregnancy test at the screening visit (Study Visit 1) and must agree to maintain effective birth control during the study.
✓. Subjects who are referred to Dr. Ellison for evaluation of normotensive hypokalemia of unknown etiology

Exclusion criteria

✕. Subject has known allergy to thiazide or sulfonamide medications
✕. Subject is pregnant or lactating.
✕. Subject has major systemic illnesses that affect potassium regulation through pathology or pharmacologic treatment. This category includes:
✕. Subject has documented kidney disease resulting in anuria, proteinuria or abnormal urinalysis, or requiring dialysis for treatment.

What they're measuring

Chloriuretic Response to a Thiaizde

Timeframe: 6 hours

Trial details

NCT IDNCT00822107

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-01

Results submitted2018-12-28

View on ClinicalTrials.gov More Gitelman Syndrome trials